APA
Click to copy
Sur, S., Lin, Z., Li, Y., Yasar, S., Rosenberg, P. B., Moghekar, A., … Lu, H. (2024). CO2 cerebrovascular reactivity measured with CBF-MRI in older individuals: Association with cognition, physical function, amyloid and tau proteins. Journal of Cerebral Blood Flow and Metabolism.
Chicago/Turabian
Click to copy
Sur, Sandeepa, Zixuan Lin, Yang Li, Sevil Yasar, Paul B. Rosenberg, A. Moghekar, Xirui Hou, et al. “CO2 Cerebrovascular Reactivity Measured with CBF-MRI in Older Individuals: Association with Cognition, Physical Function, Amyloid and Tau Proteins.” Journal of Cerebral Blood Flow and Metabolism (2024).
MLA
Click to copy
Sur, Sandeepa, et al. “CO2 Cerebrovascular Reactivity Measured with CBF-MRI in Older Individuals: Association with Cognition, Physical Function, Amyloid and Tau Proteins.” Journal of Cerebral Blood Flow and Metabolism, 2024.
BibTeX Click to copy
@article{sandeepa2024a,
title = {CO2 cerebrovascular reactivity measured with CBF-MRI in older individuals: Association with cognition, physical function, amyloid and tau proteins},
year = {2024},
journal = {Journal of Cerebral Blood Flow and Metabolism},
author = {Sur, Sandeepa and Lin, Zixuan and Li, Yang and Yasar, Sevil and Rosenberg, Paul B. and Moghekar, A. and Hou, Xirui and Jiang, Dengrong and Kalyani, Rita R and Hazel, Kaisha and Pottanat, George and Xu, Cuimei and Pillai, Jay J and Liu, Peiying and Albert, Marilyn and Lu, Hanzhang}
}
Vascular pathology is the second leading cause of cognitive impairment and represents a major contributing factor in mixed dementia. However, biomarkers for vascular cognitive impairment and dementia (VCID) are under-developed. Here we aimed to investigate the potential role of CO2 Cerebrovascular Reactivity (CVR) measured with phase-contrast quantitative flow MRI in cognitive impairment and dementia. Forty-five (69 ± 7 years) impaired (37 mild-cognitive-impairment and 8 mild-dementia by syndromic diagnosis) and 22 cognitively-healthy-control (HC) participants were recruited and scanned on a 3 T MRI. Biomarkers of AD pathology were measured in cerebrospinal fluid. We found that CBF-CVR was lower (p = 0.027) in the impaired (mean±SE, 3.70 ± 0.15%/mmHg) relative to HC (4.28 ± 0.21%/mmHg). After adjusting for AD pathological markers (Aβ42/40, total tau, and Aβ42/p-tau181), higher CBF-CVR was associated with better cognitive performance, including Montreal Cognitive Assessment, MoCA (p = 0.001), composite cognitive score (p = 0.047), and language (p = 0.004). Higher CBF-CVR was also associated with better physical function, including gait-speed (p = 0.006) and time for five chair-stands (p = 0.049). CBF-CVR was additionally related to the Clinical-Dementia-Rating, CDR, including global CDR (p = 0.026) and CDR Sum-of-Boxes (p = 0.015). CBF-CVR was inversely associated with hemoglobin A1C level (p = 0.017). In summary, CBF-CVR measured with phase-contrast MRI shows associations with cognitive performance, physical function, and disease-severity, independent of AD pathological markers.